These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37419682)

  • 41. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
    Rafael Bretón Martínez J; Martínez AC
    J Neurol Sci; 2015 Nov; 358(1-2):459-60. PubMed ID: 26279333
    [No Abstract]   [Full Text] [Related]  

  • 42. Unwarranted, long term, alglucosidase alfa enzyme replacement therapy in two non-Pompe disease patients.
    Karam C; Ragole T; Moshe-Lilie O; Chahin N
    Clin Neurol Neurosurg; 2020 Sep; 196():106048. PubMed ID: 32623214
    [No Abstract]   [Full Text] [Related]  

  • 43. Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry.
    Kishnani PS; Kronn D; Suwazono S; Broomfield A; Llerena J; Al-Hassnan ZN; Batista JL; Wilson KM; Periquet M; Daba N; Hahn A; Chien YH
    Orphanet J Rare Dis; 2023 Dec; 18(1):381. PubMed ID: 38057861
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
    Sarah B; Giovanna B; Emanuela K; Nadi N; Josè V; Alberto P
    J Neurol; 2022 Feb; 269(2):733-741. PubMed ID: 33851281
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantification of intramuscular fat in patients with late-onset Pompe disease by conventional magnetic resonance imaging for the long-term follow-up of enzyme replacement therapy.
    Lollert A; Stihl C; Hötker AM; Mengel E; König J; Laudemann K; Gökce S; Düber C; Staatz G
    PLoS One; 2018; 13(1):e0190784. PubMed ID: 29315315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients.
    Bernstein DL; Bialer MG; Mehta L; Desnick RJ
    Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.
    Angelini C; Semplicini C; Ravaglia S; Bembi B; Servidei S; Pegoraro E; Moggio M; Filosto M; Sette E; Crescimanno G; Tonin P; Parini R; Morandi L; Marrosu G; Greco G; Musumeci O; Di Iorio G; Siciliano G; Donati MA; Carubbi F; Ermani M; Mongini T; Toscano A;
    J Neurol; 2012 May; 259(5):952-8. PubMed ID: 22081099
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.
    Vanherpe P; Fieuws S; D'Hondt A; Bleyenheuft C; Demaerel P; De Bleecker J; Van den Bergh P; Baets J; Remiche G; Verhoeven K; Delstanche S; Toussaint M; Buyse B; Van Damme P; Depuydt CE; Claeys KG
    Orphanet J Rare Dis; 2020 Apr; 15(1):83. PubMed ID: 32248831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characteristics of Pompe disease in China: a report from the Pompe registry.
    Zhao Y; Wang Z; Lu J; Gu X; Huang Y; Qiu Z; Wei Y; Yan C
    Orphanet J Rare Dis; 2019 Apr; 14(1):78. PubMed ID: 30943998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The new horizons for treatment of Late-Onset Pompe Disease (LOPD).
    Guémy C; Laforêt P
    Rev Neurol (Paris); 2023; 179(1-2):81-89. PubMed ID: 36609019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of enzyme replacement therapy on bone density in late onset Pompe disease.
    Avanti M; Martin A; Columbres RC; Mozaffar T; Kimonis V
    Mol Genet Metab; 2023 Nov; 140(3):107644. PubMed ID: 37515933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study.
    de Vries JM; van der Beek NA; Hop WC; Karstens FP; Wokke JH; de Visser M; van Engelen BG; Kuks JB; van der Kooi AJ; Notermans NC; Faber CG; Verschuuren JJ; Kruijshaar ME; Reuser AJ; van Doorn PA; van der Ploeg AT
    Orphanet J Rare Dis; 2012 Sep; 7():73. PubMed ID: 23013746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
    Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
    Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease-a long-term follow-up.
    Andreassen CS; Schlütter JM; Vissing J; Andersen H
    Mol Genet Metab; 2014 May; 112(1):40-3. PubMed ID: 24685124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients.
    van der Meijden JC; Kruijshaar ME; Rizopoulos D; van Doorn PA; van der Beek NAME; van der Ploeg AT
    Orphanet J Rare Dis; 2018 May; 13(1):82. PubMed ID: 29788986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
    Pena LDM; Barohn RJ; Byrne BJ; Desnuelle C; Goker-Alpan O; Ladha S; Laforêt P; Mengel KE; Pestronk A; Pouget J; Schoser B; Straub V; Trivedi J; Van Damme P; Vissing J; Young P; Kacena K; Shafi R; Thurberg BL; Culm-Merdek K; van der Ploeg AT;
    Neuromuscul Disord; 2019 Mar; 29(3):167-186. PubMed ID: 30770310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa.
    van der Ploeg AT; Barohn R; Carlson L; Charrow J; Clemens PR; Hopkin RJ; Kishnani PS; Laforêt P; Morgan C; Nations S; Pestronk A; Plotkin H; Rosenbloom BE; Sims KB; Tsao E
    Mol Genet Metab; 2012 Nov; 107(3):456-61. PubMed ID: 23031366
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE; Beckemeyer AA; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluating avalglucosidase alfa for the management of late-onset Pompe disease.
    Angelini C
    Expert Rev Neurother; 2024 Mar; 24(3):259-266. PubMed ID: 38261315
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease.
    van der Meijden JC; Güngör D; Kruijshaar ME; Muir AD; Broekgaarden HA; van der Ploeg AT
    J Inherit Metab Dis; 2015 May; 38(3):495-503. PubMed ID: 25112389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.